Severe Acute Respiratory Syndrome coronavirus-2 is a major threat to health care worldwide with high morbidity and mortality, so it is important to understand the immunity mechanism and role of the humoral response in this disease. In this study, follow up Immunoglobulins (IgM, IgG) in COVID-19 recovered patients and correlation antibodies with age, gender and severity. Also how long antibodies level remained and provided protection against re-infection in recovered COVID 19 patients included group 1: 0-14 days after recovery, group 2: 2 months after recovery, group 3: 3 months after recovery, group4: 4-6 months after recovery, group 5: Over 6 months. The nasopharyngeal swab that use to confirm recovery via Real-Time Polymerase Chain Reaction (RT-PCR) technique. IgM and IgG antibody levels were evaluated via Enzyme Linked Immuno Florescent Assay (ELIFA) immunoassay) technique. The results showed that, the IgM levels increased during the seven days after infection to 1 month and then reduced in most patients (p≤0.05). The increased in mean of IgG in group 1, compared with other studied group, significant decrease between groups 2 vs. group1, group 3 vs. group 1, 2. Also a significant differences between groups 4 vs. group 1, 2, 3. Finally significant differences between group 5 vs. group 1, 2, 3, 4 (p≤0.05). Non-significant differences in antibodies level between male, female COVID-19 recovered patients in group 1, 2, 3, 4, 5 (p≤0.05). Finally, highly significant differences in IgG level between mild, moderate and severe subgroups in group1 and 2. The present study showed that IgM and IgG against SARS-CoV-2 appeared in the early stages of the disease and the level of IgG antibodies decreased after 1 month and could not maintain high levels during the 6-month observation period. |